FDA wants investigation into Avandia conflict: report
NEW YORK (Reuters) - The U.S. Food and Drug Administration has asked the Department of Health and Human Services to investigate whether one of the panelists at a recent safety meeting on the GlaxoSmithKline PLC drug Avandia had a conflict of interest, according to a report by the Wall Street Journal.
David Capuzzi, an endocrinologist in Philadelphia, has received $14,000 from Glaxo for speaking on behalf of another drug, Lovaza, according to the newspaper report.
Capuzzi said he told the FDA about his connection to Glaxo and the FDA said it had vetted all members of its advisory panel for conflicts, the newspaper reported.
- Tweet this
- Share this
- Digg this
- Apple sells more than 10 million new iPhones in first 3 days
- UPDATE 3-Apple sells more than 10 mln new iPhones in first 3 days
- India's Mars mission a step closer to success with engine test
- Israel's Mossad takes hunt for foreign spies and informants online
- Modi to observe strict fast during maiden trip to U.S.
Sierra Leone recorded 130 new cases of the Ebola virus during a three-day lockdown and it is waiting for test results on a further 39 suspected cases, Stephen Gaojia, head of the Ebola Emergency Operations Centre, said on Monday. Full Article
Allowing blood donations from gay men could help save over a million lives: U.S. study. Full Article